Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Articles online first > Minerva Ginecologica 2017 Mar 14

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA GINECOLOGICA

Rivista di Ostetricia e Ginecologia


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

Minerva Ginecologica 2017 Mar 14

DOI: 10.23736/S0026-4784.17.04043-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Current evidence and emerging drug therapies for overactive bladder

Matthew IZETT, Martino ZACCHE, Ganesh THIAGAMOORTHY, Dudley ROBINSON, Linda CARDOZO

Department of Urogynaecology, King’s College Hospital NHS Foundation Trust, London, UK


PDF  


Overactive bladder is a common symptom complex with health related quality of life impacts on the individual as well as utilising health resources. Antimuscarinic therapy has been the mainstay of treatment and is well supported within the literature and guidelines. However, compliance is poor due to lack of efficacy and adverse events leading to the development of novel therapies. Mirabegron, the B3-adrenoreceptor agonist has emerged as an evidence-based alternative first or second line therapy. Two decades after its first clinical application for overactive bladder, intravesical botulinum toxin is now an important part of any clinician’s armamentarium for refractory cases. Despite these therapeutic options many patients find therapies ineffective or have adverse events. This has resulted in ongoing developments in the understanding of overactive bladder, potential new drugs and combination therapies, which this paper intends to review.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

linda@lindacardozo.co.uk